Project Grant R43NS129414
Award Date
9/15/23
Completion Date
8/31/24
Dollars Obligated
$462K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), supports research on a novel enzyme delivery system for treating neuronopathic Gaucher disease (NGD). The $653,309 award will fund the development of a brain-targeted nanocarrier, called SAPC-DOPS, that can deliver a stable form of the enzyme acid β-glucosidase (FGCase) across the blood-brain barrier to address the neurological impacts of...
This $1,369,242 project grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to develop an adeno-associated virus (AAV) gene therapy product for treating Mucopolysaccharidosis (MPS) IIIB, a rare lysosomal storage disease. The key objectives are to: 1) Engineer and optimize large-scale manufacturing processes for the AAV9-based gene therapy vector...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,923 Project Grant to Biostrategies LC under the Child Health and Human Development Extramural Research program (CFDA 93.865). The purpose of the award is to develop a "delivery-enhanced" gene therapy drug comprising an RTB:GALNS fusion protein for treating the rare metabolic disorder Mucopolysaccharidosis Type IVA (Morquio A Syndrome). The key objectives are to: 1) optimize the RTB:GALNS construct for...
The Project Grant award R01NS136487, entitled "Microglia Replacement Using Engineered HSCs for Treatment of Leukodystrophies", is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $694,134 award, which runs from April 15, 2025 to March 31, 2030, supports research to enhance the engraftment of genetically modified autologous hematopoietic stem...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program provides $494,040 in funding to Mark Therapeutics, Inc. to develop a first-in-class disease-modifying gene therapy for idiopathic Parkinson's disease (IDPD). The goal is to optimize and validate new adeno-associated viral (AAV) gene therapy candidates that can compensate for the...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports pre-clinical testing of a novel gene therapy for a pediatric neurodegenerative disease. The $419,482 award to the University of Texas Southwestern Medical Center (UT Southwestern) aims to evaluate the efficacy and safety of the AAV9-HVAC14OPT gene therapy in treating...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $2,285,718 to the University of Florida to advance the development of an AAVtcm8-conNAGLU gene therapy vector for the treatment of Sanfilippo Syndrome Type B. The project aims to perform preclinical development activities required for Investigational New Drug (IND)...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research into the development of a gene therapy treatment for Charcot-Marie-Tooth disease type 2D (CMT2D). The $1,271,545 award will fund the optimization of an adeno-associated virus (AAV) vector carrying tRNA genes to replace the defective tRNA synthetase enzyme...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $299,648 to Cometa Therapeutics Inc. to conduct enabling studies for CMT-101, a novel gene therapy for Glycogen Storage Disease 1B (GSD-1B). The funding will support preclinical development activities, including dose-finding and biodistribution studies, a pre-Investigational New...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $794,967 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to develop a murine glioblastoma model for evaluating oncolytic herpes simplex virus (HSV) therapy. The key objective is to create a mouse model with brain tumors that are permissive to HSV-1 infection. This...